Jing Marantz
About Jing Marantz
Chief Medical Officer of Scholar Rock since November 9, 2022; age 60 as of March 31, 2025. Education: MD (Tongji Medical College), PhD in Biochemistry & Molecular Biology (Medical University of South Carolina), MBA (UC Berkeley) . Prior roles span medical affairs and business leadership at Alnylam, Acceleron, Alexion, Biogen, ARIAD, Millennium; she led global medical launches of ONPATTRO and GIVLAARI at Alnylam . Company performance during her tenure: value of an initial $100 investment rose to $173.99 by FY2024 (TSR), while net income was a loss of $246 million in 2024 .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Krystal Biotech | Executive Vice President & Chief Business Officer | Jan 2022–Aug 2022 | Senior BD leadership; served on board the prior year |
| Acceleron Pharma | SVP, Medical Affairs | Oct 2020–Jan 2022 | Member of R&D leadership, safety and product development committees |
| Alnylam Pharmaceuticals | SVP, Medical Affairs | Jun 2018–Sep 2020 | Built global medical footprint across 19 countries; launched ONPATTRO & GIVLAARI |
| Alexion Pharmaceuticals | VP Global Medical Affairs; Head of U.S.; Interim Head Latin America | Prior to 2018 | Led complement franchise in hematology, nephrology, neurology |
| Biogen; ARIAD; Millennium | Various leadership roles | Earlier career | Development and medical affairs leadership roles |
External Roles
| Organization | Role | Years | Notes |
|---|---|---|---|
| Arcturus Therapeutics (NASDAQ: ARCT) | Director | Dec 2021–present | Current public company board |
| Krystal Biotech (NASDAQ: KRYS) | Director | Jan 2021–Jan 2022 | Prior public company board |
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Base Salary ($) | 465,000 | 493,000 |
| Target Bonus (% of Base) | 40% | 40% |
| Actual Bonus Paid ($) | 2024 |
|---|---|
| Non-Equity Incentive Plan Compensation | 246,500 |
Performance Compensation
| Award Type | Grant Date | Shares/Units | Grant-Date Fair Value ($) | Vesting |
|---|---|---|---|---|
| RSUs | 2/12/2024 | 72,855 | 1,147,466 | 4 equal annual installments; first on Jan 15, 2025 |
| Stock Options | 2/12/2024 | 97,145 (18,214 exercisable; 78,931 unexercisable at 12/31/24) | 1,175,649 | 16 equal quarterly installments; first on Apr 1, 2024; strike $15.75; exp. 2/12/2034 |
| Inducement Stock Options | 11/14/2022 | 130,000 (5,000 exercisable; 125,000 unexercisable at 12/31/24) | — | 25% on Nov 9, 2023; remainder quarterly over 12 quarters; strike $8.59; exp. 11/14/2032 |
Annual cash bonus is driven by corporate goals and individual performance (85% corporate/15% individual for non-CEO NEOs) .
Equity Ownership & Alignment
| As of March 26, 2025 | Shares Owned | Options Exercisable within 60 Days | Ownership % of Outstanding | Hedging/Pledging Policy |
|---|---|---|---|---|
| Jing Marantz | 12,558 | 69,464 | <1% (asterisk denotes less than 1%) | Company prohibits hedging and pledging of company stock |
| Unvested RSUs (Market Value at 12/31/24) |
|---|
| 72,855 units; $3,148,793 market value based on $43.22 close on 12/31/24 |
Employment Terms
| Scenario | Cash Severance | Bonus Severance | Health (COBRA) | Equity Vesting |
|---|---|---|---|---|
| Termination without Cause or for Good Reason (no CIC) | 9 months base salary | — | Employer contribution for up to 9 months | — |
| Termination without Cause or for Good Reason within 18 months after Change in Control | 12 months base salary | 1.0× annual target bonus | Employer contribution for up to 12 months | Immediate acceleration of time-based equity |
| Employment Status | At-will; standard indemnification agreement | — | — | — |
| Restrictive Covenants | Non-competition may be required for 1 year as a condition to severance payments | — | — | — |
| Clawback | Compensation Recovery Policy adopted Nov 28, 2023; no recoveries required as of FY2024 |
Performance & Pay Linkage Snapshot
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total Shareholder Return ($100 initial investment) | 36.43 | 75.68 | 173.99 |
| Net Income (loss, $ millions) | (135) | (166) | (246) |
Investment Implications
- Pay mix emphasizes time-based equity (options and RSUs), aligning upside with share price performance and encouraging retention; no performance-vesting equity disclosed to date . Hedging/pledging prohibitions strengthen alignment by preventing downside protection or leverage .
- Annual RSU vest dates (e.g., Jan 15 each year for 2024 grants) create predictable potential Form 4 activity and incremental supply from vesting; options from 2024 grants vest quarterly through 2028 .
- Severance economics are moderate absent change-in-control (9 months base), but move to 12 months base plus 1x target bonus and full time-based acceleration on CIC terminations, implying standard double-trigger protection and manageable dilution from accelerated vesting .
- Ownership is <1% of outstanding shares, but meaningful unvested RSUs and multi-year option schedules provide continued retention incentives tied to program execution milestones in SMA and oncology .
No material legal proceedings involving Dr. Marantz were disclosed; none noted for executive officers .